The two abstracts from this year's ASCO meeting - Single-Agent LV305 Induces Anti-tumor Immune And Clinical Responses In Patients With Advanced Or Metastatic Sarcoma And Other Cancers Expressing NY-ESO-1 http://www.immunedesign.com/wp-content/uploads/2016/06/LV305-ASCO-poster-2016-final-31May2016-v01.pdf and Pilot Trial Of Intratumoral G100, A Toll-like Receptor-4 (TLR4) Agonist, In Patients With Merkel Cell Carcinoma: Final Clinical Results And Immunologic Effects On The Tumor Microenvironment http://www.immunedesign.com/wp-content/uploads/2016/06/MCC-ASCO-poster-final-31May2016-v01.pdf